21 February 2018 - - East Hanover, New Jersey-based healthcare solutions provider Novartis Pharmaceuticals Corp. has presented additional results from the SCULPTURE study at the 2018 American Academy of Dermatology annual meeting in San Diego, California, the company said.
Two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx (secukinumab) reported no impact of skin disease on their quality of life through 5 years, as described by the Dermatology Life Quality Index 0/1 response, a questionnaire used to evaluate the impact of skin disease on a patient's quality of life.
Study findings also show absolute PASI ≤1/≤2/≤3 responses at year 1 (58.6%, 67.9% and 74.1%, respectively) were sustained to year 5 (53.3%, 66.4% and 75.4%, respectively).
Achievement of an absolute PASI score lower than 2 or 3 has been proposed as an indication of treatment success.
The most common adverse events included nasopharyngitis, upper respiratory tract infection, and headache, consistent with those reported in the core study and previous Phase III studies.
Cosentyx is a fully human IL-17A antagonist approved to treat ankylosing spondylitis, psoriatic arthritis, and moderate to severe plaque psoriasis. To date, more than 140,000 patients worldwide have been prescribed Cosentyx in the post-marketing setting across all indications.
The Cosentyx SCULPTURE study is a multicenter, double-blind and open-label, 4-year extension to the core Phase III SCULPTURE study.
Novartis Pharmaceuticals is an affiliate of Novartis which provides innovative healthcare solutions that address the evolving needs of patients and societies.